Infliximab-Induced Vanishing Bile Duct Syndrome.

Michael J Eiswerth, Matthew A Heckroth, Ali Ismail, Dibson D Gondim, Ryan Kaufman

Open access · diamondAbstract readCase Reports

In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.7field-weighted citation impact, top 34% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

Non-invasive biomarkers for identification of vanishing bile duct syndrome among children with acute cholestatic hepatitis.Translational pediatrics · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael J EiswerthDepartment of Internal Medicine, University of Louisville Hospital, Louisville, USA.

Matthew A HeckrothDepartment of Internal Medicine, University of Louisville Hospital, Louisville, USA.

Ali IsmailDepartment of Pathology, University of Louisville Hospital, Louisville, USA.

Dibson D GondimDepartment of Pathology, University of Louisville Hospital, Louisville, USA.

Ryan KaufmanDepartment of Internal Medicine, University of Louisville Hospital, Louisville, USA.

University of Louisville Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) is a spectrum of pathology that can be classified by mechanism of injury or by type of observed hepatotoxicity. Vanishing bile duct syndrome (VBDS) is a group of acquired and genetic disorders that cause the destruction and disappearance of intrahepatic bile ducts, and cholestasis. VBDS typically presents with severe cholestatic hepatitis and can have immunoallergic features. Infliximab has been reported to rarely cause a cholestatic pattern of liver injury due to ductopenia characteristic of VBDS. Herein we present a clinical case of infliximab-induced DILI resulting in VBDS.

Indexed as

cholestatic liver injurydrug induced liver injuryelevated liver transaminasesinfliximabvanishing bile duct syndrome

Identifiers

PMID35273881

DOI10.7759/cureus.21940

PMCPMC8901196

OpenAlexW4210255720

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.